Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dana Vered

Licensed Practical Nurse Southfield, MI Nurse Practitioner

NPI 1568935468 CMS profile 10788964

29355 Northwestern Hwy Ste 302, Southfield, MI 48034

Open in the dashboard

General payments

$10,412

515 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dana Vered of Southfield, MI is reported in the CMS Open Payments database as having received $10,412 across 515 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Licensed Practical Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,915 150
2024 General $3,258 161
2023 General $2,101 100
2022 General $1,255 56
2021 General $883 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dana Vered
  • Licensed Practical Nurse median
  • Middle half of Licensed Practical Nurse
  • National median

In program year 2025, general payments to Dana Vered were reported at $2,915. Among 149 Licensed Practical Nurse profiles paid that year, the median was $39 and the middle half received between $23 and $109.

Show as a table
Year Dana Vered Licensed Practical Nurse median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $883 $29 $19–$120 $132
2022 $1,255 $35 $19–$122 $149
2023 $2,101 $51 $18–$125 $160
2024 $3,258 $53 $23–$139 $164
2025 $2,915 $39 $23–$109 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,888 97 payments
  2. Incyte Corporation $1,161 55 payments
  3. Genzyme Corporation $1,071 32 payments
  4. Janssen Biotech, Inc. $866 39 payments
  5. Pfizer Inc. $827 50 payments
  6. Regeneron Healthcare Solutions, Inc. $724 25 payments
  7. Novartis Pharmaceuticals Corporation $483 46 payments
  8. Sun Pharmaceutical Industries Inc. $472 29 payments
  9. E.R. Squibb & Sons, L.L.C. $463 21 payments
  10. Lilly USA, LLC $420 21 payments
  11. Other $2,037 100 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,166 512 payments
  2. Education $246 3 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,371 39 payments
  2. OPZELURA $1,161 55 payments
  3. RINVOQ $898 43 payments
  4. TREMFYA $702 31 payments
  5. CIBINQO $659 41 payments
  6. SKYRIZI $524 32 payments
  7. EUCRISA $517 35 payments
  8. DUPIXENT Inflammation And Immunology $487 16 payments
  9. COSENTYX $465 45 payments
  10. SOTYKTU $423 19 payments
  11. Other $5,231 271 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

264

Median for Nurse Practitioner: 389

Drug cost

$7,650

Median for Nurse Practitioner: $21,885

Branded share of claims

4.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tacrolimus Generic 27 $2,791
Ammonium Lactate Generic 39 $1,126
Ketoconazole Generic 43 $1,001
Clobetasol Propionate Generic 27 $753
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 11 $684
Triamcinolone Acetonide Generic 48 $569
Mupirocin Generic 40 $311
Clindamycin Phosphate Generic 13 $281
Minoxidil Generic 16 $133

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$28,861

Of which drugs: $33

Medicare patients

163

Average age 74

Services billed

722

109 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 51%
Ischemic heart disease 30%
Diabetes 26%
Chronic kidney disease 23%
Depression 21%
Osteoporosis 20%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 44 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $415
  • Regeneron Healthcare Solutions, Inc. $247
$661 — —
OPZELURA
  • Incyte Corporation $510
$510 — —
TREMFYA
  • Janssen Biotech, Inc. $340
$340 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $281
$281 — —
SKYRIZI
  • AbbVie, Inc. $239
$239 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

515 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Licensed Practical Nurse in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record